These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
374 related articles for article (PubMed ID: 35431540)
1. Design, Synthesis, and Biological Evaluation of 2-Anilino-4-Triazolpyrimidine Derivatives as CDK4/HDACs Inhibitors. Wang S; Han S; Cheng W; Miao R; Li S; Tian X; Kan Q Drug Des Devel Ther; 2022; 16():1083-1097. PubMed ID: 35431540 [TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening. Liu J; Zhou J; He F; Gao L; Wen Y; Gao L; Wang P; Kang D; Hu L Eur J Med Chem; 2020 Apr; 192():112189. PubMed ID: 32151834 [TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors. Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899 [TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. Cheng C; Yun F; He J; Ullah S; Yuan Q Eur J Med Chem; 2019 Jul; 173():185-202. PubMed ID: 31003060 [TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents. Xie R; Li Y; Tang P; Yuan Q Eur J Med Chem; 2018 Jan; 143():320-333. PubMed ID: 29202397 [TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, and Biological Evaluation of New Urushiol Derivatives as Potent Class I Histone Deacetylase Inhibitors. Zhou H; Qi Z; Liu D; Xue X; Wang C Chembiochem; 2023 Sep; 24(18):e202300238. PubMed ID: 37366008 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents. Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133 [TBL] [Abstract][Full Text] [Related]
8. Synthesis, antitumor, and apoptosis-inducing activities of novel 5-arylidenethiazolidine-2,4-dione derivatives: Histone deacetylases inhibitory activity and molecular docking study. Hamdi A; Elhusseiny WM; Othman DIA; Haikal A; Bakheit AH; El-Azab AS; Al-Agamy MHM; Abdel-Aziz AA Eur J Med Chem; 2022 Dec; 244():114827. PubMed ID: 36242988 [TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis and Biological Evaluation of New HDAC1 and HDAC2 Inhibitors Endowed with Ligustrazine as a Novel Cap Moiety. Al-Sanea MM; Gotina L; Mohamed MF; Grace Thomas Parambi D; Gomaa HAM; Mathew B; Youssif BGM; Alharbi KS; Elsayed ZM; Abdelgawad MA; Eldehna WM Drug Des Devel Ther; 2020; 14():497-508. PubMed ID: 32103894 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of 4-anilinothieno[2,3-d]pyrimidine-based hydroxamic acid derivatives as novel histone deacetylase inhibitors. Yang W; Li L; Ji X; Wu X; Su M; Sheng L; Zang Y; Li J; Liu H Bioorg Med Chem; 2014 Nov; 22(21):6146-55. PubMed ID: 25261927 [TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and antitumor activities of phthalazinone derivatives as PARP-1 inhibitors and PARP-1/HDAC-1 inhibitors. Wu J; Wang X; Yao Y; Du N; Duan L; Gong P Bioorg Chem; 2024 Oct; 151():107556. PubMed ID: 39068717 [TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors. Yuan Z; Sun Q; Li D; Miao S; Chen S; Song L; Gao C; Chen Y; Tan C; Jiang Y Eur J Med Chem; 2017 Jul; 134():281-292. PubMed ID: 28419930 [TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of coumarin-based N-hydroxycinnamamide derivatives as novel histone deacetylase inhibitors with anticancer activities. Ding J; Liu J; Zhang Z; Guo J; Cheng M; Wan Y; Wang R; Fang Y; Guan Z; Jin Y; Xie SS Bioorg Chem; 2020 Aug; 101():104023. PubMed ID: 32650178 [TBL] [Abstract][Full Text] [Related]
14. Utilization of cyanopyridine in design and synthesis of first-in-class anticancer dual acting PIM-1 kinase/HDAC inhibitors. Bass AKA; Nageeb EM; El-Zoghbi MS; Mohamed MFA; Badr M; Abuo-Rahma GEA Bioorg Chem; 2022 Feb; 119():105564. PubMed ID: 34959179 [TBL] [Abstract][Full Text] [Related]
15. Synthesis, biological evaluation, and molecular docking analysis of novel linker-less benzamide based potent and selective HDAC3 inhibitors. Routholla G; Pulya S; Patel T; Abdul Amin S; Adhikari N; Biswas S; Jha T; Ghosh B Bioorg Chem; 2021 Sep; 114():105050. PubMed ID: 34120025 [TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of novel histone deacetylase (HDAC) inhibitors derived from Gao Y; Duan J; Dang X; Yuan Y; Wang Y; He X; Bai R; Ye XY; Xie T J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2195991. PubMed ID: 37013860 [No Abstract] [Full Text] [Related]
17. Design, Synthesis, Molecular Modeling, and Biological Evaluation of Novel Amine-based Histone Deacetylase Inhibitors. Abdelkarim H; Neelarapu R; Madriaga A; Vaidya AS; Kastrati I; Karumudi B; Wang YT; Taha TY; Thatcher GRJ; Frasor J; Petukhov PA ChemMedChem; 2017 Dec; 12(24):2030-2043. PubMed ID: 29080240 [TBL] [Abstract][Full Text] [Related]
18. Development of Coumarin-Based Hydroxamates as Histone Deacetylase Inhibitors with Antitumor Activities. Zhao N; Yang F; Han L; Qu Y; Ge D; Zhang H Molecules; 2020 Feb; 25(3):. PubMed ID: 32046013 [TBL] [Abstract][Full Text] [Related]
19. β-Carboline tethered cinnamoyl 2-aminobenzamides as class I selective HDAC inhibitors: Design, synthesis, biological activities and modelling studies. Namballa HK; Anchi P; Lakshmi Manasa K; Soni JP; Godugu C; Shankaraiah N; Kamal A Bioorg Chem; 2021 Dec; 117():105461. PubMed ID: 34753060 [TBL] [Abstract][Full Text] [Related]
20. Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity. Cheng C; Yun F; Ullah S; Yuan Q Eur J Med Chem; 2020 Mar; 189():112073. PubMed ID: 31991336 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]